Navigation Links
Lilly and Incyte Announce Baricitinib Efficacy and Safety Data from the Open-Label, Long-Term Extension of the Phase 2b JADA Study in Patients with Rheumatoid Arthritis
Date:6/13/2013

tal Sciences in the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences at the University of Oxford, and steering committee member for the study.

A copy of the EULAR oral presentation can be accessed at:  2013 EULAR - JADA 52-Week Presentation  

Trial DesignThis randomized, open-label, long-term extension of Phase 2b JADA study included 201 (95 percent) of the eligible 212 patients. Of the 201 patients, 184 completed 52 weeks of treatment, 15 discontinued treatment, and two patients had not yet completed the full 52 weeks of treatment. Patients received either 4 mg or 8 mg once-daily doses of baricitinib beginning at week 24 through week 52.

In the initial 12-week treatment duration, patients received one of four doses of baricitinib (1 mg, 2 mg, 4 mg or 8 mg) or placebo, administered once daily. In the 12- to 24-week portion of the study, patients initially randomized to placebo or the 1 mg baricitinib dose were re-randomized to receive either 4 mg once daily or 2 mg twice daily for an additional 12 weeks; patients initially randomized to the 2 mg, 4 mg and 8 mg doses continued therapy with those doses.

Patients who completed week 24 were eligible to receive either the 4- or 8-mg once daily dose through week 52. The study is ongoing, with all patients who are continuing in the study receiving baricitinib 4 mg once daily.

About JAK InhibitionThere are four known JAK enzymes: JAK1, JAK2, JAK3 and TYK2.[3] These enzymes are critical components of signaling mechanisms used by a number of cytokines and growth factors, including several that are elevated in patients with RA. Cytokines such as interleukin-6, -12 and -23 and both type 1 and type 2 interferons signal through these pathways. JAK-dependent cytokines have been implicated in the pathogenesis of a number of inflammatory and autoi
'/>"/>

SOURCE Eli Lilly and Company; Incyte Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Lilly to Present at Goldman Sachs Global Healthcare Conference
2. Lilly Acquires Novel Tau Tangle Diagnostic Program to Bolster Alzheimers Disease Research and Development
3. Lilly and Incyte Announce Additional Phase IIb Baricitinib Data, Including MRI Results, in Patients with Rheumatoid Arthritis
4. SHAREHOLDER ALERT: The Law Firm of Levi & Korsinsky Notifies Investors with Losses on Their Investment in Incyte Corporation of Class Action Lawsuit and the May 6, 2013 Lead Plaintiff Deadline
5. Todays Research on Incyte and Arena Pharma: Biotech Stocks Up on Drug Approvals
6. Steep Hill Laboratories and Halent Scientific Proudly Announce Historic Merger
7. Andain Inc. Announces 2,000 Units Initial Production of the Breakthrough Miniature Disposable Insulin Pump for Use in Clinical Trials for Type-I and Type-II Diabetes
8. Verenium Announces Appointment Of Brian Carter As Vice President Of Grain Processing
9. Neogen announces Bohannon retirement, successor named
10. BioDelivery Sciences Announces NDA Submission for BUNAVAIL on Track Following Positive Pre-NDA Meeting with FDA
11. Hemostemix Announces Formation of Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... SAN DIEGO, Aug. 29, 2014  Pfenex Inc. ... in the development of high-value and difficult to ... business update and reported financial results for the ... "With the successful completion of our initial public ... advance our biosimilar product candidates, derived from our ...
(Date:8/29/2014)... , Aug. 29, 2014 /PRNewswire/ - iCo Therapeutics ... today reported financial results for the six months ... are expressed in Canadian dollars and presented under ... Quarter 2014 Highlights , Announced top-line ... (VA) primary endpoint for subjects enrolled in the ...
(Date:8/29/2014)... 29, 2014 Intrinsic Imaging, an ... GAMP® 5 compliant imaging core lab, announced today ... II clinical trial to assess a new treatment ... trial, Intrinsic Imaging will provide comprehensive imaging core ... and charter development, site qualification, site training and ...
(Date:8/28/2014)... A new research platform uses a ... tiny structures undergoing stress and heating, an ... designs for microelectronics and batteries., This new ... about how heating and the surface stress ... Researchers have discussed the merits of surface-stress ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8iCo Therapeutics Announces Second Quarter 2014 Financial Results 2iCo Therapeutics Announces Second Quarter 2014 Financial Results 3iCo Therapeutics Announces Second Quarter 2014 Financial Results 4Intrinsic Imaging Awarded Phase II Clinical Trial to Assess New Treatment for Non-Hodgkin’s Lymphoma 2New analytical technology reveals 'nanomechanical' surface traits 2New analytical technology reveals 'nanomechanical' surface traits 3
... Summary: Genmab Announced Today it has Amended the Ongoing HuMax-CD4, ... Received an Orphan Drug ... COPENHAGEN, Denmark, October 11 Genmab A/S,(OMX: GEN) announced ... of HuMax-CD4(R) (zanolimumab) to treat refractory cutaneous T-cell,lymphoma (CTCL) patients. ...
... 10 The National,Institutes of Allergy and Infectious ... Bavarian Nordic to include the initiation of,a larger ... vaccine, in persons diagnosed with atopic dermatitis. The ... and has a value of,US$15 million, with the ...
... 10 Monogram,Biosciences, Inc. (Nasdaq: MGRM ) ... and Chief Financial Officer, is,scheduled to present a ... Tuesday, November 13, 2007 at 11:00 a.m. (Eastern ... To access the live audio broadcast or ...
Cached Biology Technology:Genmab Amends HuMax-CD4 Pivotal Study in CTCL 2Genmab Amends HuMax-CD4 Pivotal Study in CTCL 3Government Expands Trial With IMVAMUNE(R) Smallpox Vaccine in Persons With Atopic Dermatitis/Eczema 2Government Expands Trial With IMVAMUNE(R) Smallpox Vaccine in Persons With Atopic Dermatitis/Eczema 3Monogram Biosciences to Present at the JMP Securities Healthcare Conference 2
(Date:8/29/2014)... release is available in German . ... players in the natural nitrogen cycle on Earth and ... bacteria were thought to depend on nitrite as their ... by Holger Daims, a microbiologist at the University of ... hydrogen as an alternative source of energy. The oxidation ...
(Date:8/29/2014)... USA - The rise of the Tibetan plateau -- ... -- is important for both its profound effect on ... study published in GSA Bulletin , Katharine Huntington ... isotope thermometry -- using modern and fossil snail shells ... in southwestern Tibet. , Views range widely on ...
(Date:8/28/2014)... German . The ... a striking pattern of blue stripes alternating with golden stripes. ... and yellow cells emerge during growth in the skin of ... to compose the characteristic colour pattern. ,While it ... to form proper stripes, the embryonic origin of the pigment ...
Breaking Biology News(10 mins):Hydrogen powers important nitrogen-transforming bacteria 2Hydrogen powers important nitrogen-transforming bacteria 3Snails tell of the rise and fall of the Tibetan Plateau 2Snails tell of the rise and fall of the Tibetan Plateau 3Snails tell of the rise and fall of the Tibetan Plateau 4Snails tell of the rise and fall of the Tibetan Plateau 5Snails tell of the rise and fall of the Tibetan Plateau 6Snails tell of the rise and fall of the Tibetan Plateau 7How the zebrafish gets its stripes 2How the zebrafish gets its stripes 3
... approved to treat multiple sclerosis may also hold promise for ... that often leads to heart failure, researchers at the University ... findings are published in the July 16 issue of ... thickening of the heart muscle that shrinks the interior ...
... in an international study which has revealed the genetic secrets ... the most hostile environments on earth. The ground tit ... largest high-altitude land mass in the world. This study has ... how it copes with the extreme living conditions of this ...
... avian H7N9 influenza that emerged in China this year have ... the infection, but testing for antiviral resistance can give misleading ... The authors of a study published in mBio , ... characterized viruses taken from the first person known to be ...
Cached Biology News:MS drug shows promise for preventing heart failure 2Genetic secrets of the world's toughest little bird 2Genetic secrets of the world's toughest little bird 3H7N9 influenza strain resistant to antivirals, but tests fail to identify resistance 2H7N9 influenza strain resistant to antivirals, but tests fail to identify resistance 3
... a member of the caudal-related homeobox family, ... both proliferation and differentiation in intestinal epithelial ... triggering cells towards the phenotype of differentiated ... maintenance of the phenotype. Clone CDX2-88 reacts ...
Anti-GOSR2 Monoclonal AntibodyOther Sub-Family: not assigned-Other Applications: Immunocytochemistry, Immunoprecipitation, Western Blot...
V beta 5 Purified Anti-Human clone MH3-2, Isotype Mouse IgG 2a , kappa, 0.1 mg Consult technical datasheet for details....
Monoclonal Anti-Cystatin A tissue culture supernatant Solution containing 15 mM sodium azide human cystatin A ...
Biology Products: